Suzanne Lepage

About a million Canadians are impacted by rare diseases, which disproportionately affect younger patients — 70 per cent start in childhood and, sadly, half of these children won’t reach adulthood, said Suzanne Lepage, a private health plan strategist, during a session supported by Alexion Pharmaceuticals at Benefits Canada‘s 2022 Face to Face Drug Plan Management Forum […]

  • January 23, 2023 May 16, 2023
  • 07:54

While vaccine coverage varies across provincial drug plans, several million Canadians who are members of private drug plans don’t have coverage at all, according to Chris Bonnett (pictured left), founder and principal consultant of H3 Consulting, during a panel session supported by GSK, Merck & Co. Inc. and Pfizer Canada Inc. at Benefits Canada’s 2022 […]

  • January 23, 2023 January 20, 2023
  • 07:53

Living with a rare chronic disease while also managing an employer-sponsored benefits plan provides Chris MacLeod with a unique perspective. During a session supported by Vertex Pharmaceuticals at Benefits Canada’s 2022 Face to Face Drug Plan Management Forum in Toronto in December, MacLeod, the founding partner at Cambridge LLP, said he was diagnosed with cystic fibrosis […]

  • January 23, 2023 January 17, 2023
  • 07:52

Approximately three million Canadians live with asthma, a chronic inflammatory disease that affects airways, limits airflow and makes breathing difficult, said Dr. Erika Penz, associate professor in respirology, critical care and sleep medicine at the University of Saskatchewan, during a webinar hosted by Benefits Canada and sponsored by GSK in November. Asthma, which affects people of […]

  • December 22, 2022 December 19, 2022
  • 09:00

Canada has one of the highest incidence rates of inflammatory bowel disease in the world. “We don’t know why, but Canada is one of the hotspots,” said Dr Mark Silverberg, gastroenterologist at Mount Sinai Hospital and the University of Toronto, during a webinar hosted by Benefits Canada and sponsored by Takeda Canada in November. IBD […]

  • November 29, 2022 November 29, 2022
  • 09:00

According to conservative estimates, 100,000 Canadians may suffer from hypertrophic cardiomyopathy with an estimated prevalence of about one in every 200 to 500 individuals, said Dr. Bobby Heydari, a cardiologist and associate professor of medicine at the University of Calgary, during a webinar hosted by Benefits Canada and sponsored by the Bristol-Myers Squibb Co. Patients’ mean […]

  • September 9, 2022 September 9, 2022
  • 09:00

Severe asthma is a complex condition that impacts between 150,000 and 250,000 Canadians, according to Vanessa Foran, president and chief executive officer of Asthma Canada, during a webinar hosted last month by Benefits Canada and supported by AstraZeneca. It’s an acute condition where people have difficulty achieving control of their disease despite proper use of […]

  • July 6, 2022 August 15, 2022
  • 09:00

A British Columbia labour arbitration decision is providing insight on how a block level implementation of a benefits provider’s drug cost-control program violated a collective agreement in a unionized workplace. The Douglas College Faculty Association grieved the implementation of Manulife’s DrugWatch program contravened their collective agreement, which ensured “there will be no change to the […]

  • May 16, 2022 May 17, 2022
  • 09:00

A migraine attack is much more severe than a headache because it comes with a lot of other symptoms, according to Dr. Elizabeth Leroux, a neurologist, president of the Canadian Headache Society and chair of Migraine Canada, speaking during a session supported by Abbvie at Benefits Canada‘s Chronic Disease at Work event in February. Migraine, […]

  • March 7, 2022 March 3, 2022
  • 07:59

“Diabetes is a disease that you do not see from the outside,” said Kayla O’Connell, who lives with type 1 diabetes and is a sales support associate at Medtronic, during a session at Benefits Canada‘s 2022 Chronic Disease at Work event in February. About 10 per cent of Canadians with diabetes have type 1, while […]

  • March 7, 2022 March 3, 2022
  • 07:57